From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e(eIF4e).eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188) . eIF4E-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Eif4e Mouse Pre-designed siRNA Set A contains three designed siRNAs for Eif4e gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
EIF4E Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Eif4e Rat Pre-designed siRNA Set A contains three designed siRNAs for Eif4e gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
eIF4E-IN-3 is a potent inhibitor of eukaryotic initiation factor 4e(eIF4e).eIF4E-IN-3 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 485) .
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical
activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study .
eIF4E/eIF4G PPI-IN-1 is an eIF4E/eIF4G interaction inhibitor with a KD of 20.2 μM for eIF4E protein. eIF4E/eIF4G PPI-IN-1 plays an antitumor role in multiple modes of action including regulating the activity ofeIF4E by inhibiting the Ras/MAPK/eIF4E signaling pathway, apoptosis and cell migration. eIF4E/eIF4G PPI-IN-1 suppresses the growth of HepG2 xenografts in nude mice and was relatively nontoxic to mice .
eIF4E-IN-6(compound 4b) is a GMP analogs synthesized to targeteIF4Eand restrain its binding to cap mRNA.eIF4E-IN-6shows cell cytotoxicity against Caco-2, HepG-2,and MCF-7 cells, withIC50values of 31, 27, and 21 μM, respectively .
EIF4E2 Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
EIF4E3 Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
(Z)-4EGI-1 is the Z-isomer of 4EGI-1 and is an inhibitor of eIF4E/eIF4G interaction and of translation initiation. (Z)-4EGI-1 effectively binds to eIF4E with an IC50 of 43.5 μM and a Kd value of 8.74 μM. (Z)-4EGI-1 has anticancer activity .
ETP-45835 is slective and potent MNK inhibitor with IC50s of 575 nM and 646 nM for MNK1 and MNK2, respectively. ETP-45835 shows little activity against 24 other kinases. ETP-45835 inhibits eIF4E Ser209 phosphorylation in cells, and has anticancer effects .
MNK1/2-IN-7 (compound 20j) is an orally available inhibitor of MNK1/2 with anticancer activity and hERG safety. MNK1/2-IN-7 also inhibits the phosphorylation of eIF4E, inhibiting the MNK/eIF4E signaling pathway and cancer cell proliferation. MNK1/2-IN-7 is synergistic with Ibrutinib (HY-109970) .
NUCC-0200808 (Compound 12g) is an inhibitor of MNK1 with an IC50 of 42 nM. NUCC-0200808 reduces eIF4E phosphorylation and cell viability in AML cells, and induces apoptosis. NUCC-0200808 holds promise for research in the field of leukemia .
Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).
EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation .
Tomivosertib hydrochlorideis a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib hydrochloride treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib hydrochloride also dramatically downregulates PD-L1 protein abundance .
Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
m7GpppAmpG (m7G(5')ppp(5')(2'OMeA)pG) is a trinucleotide 5′ end cap analog. m7GpppAmpG binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG caps RNA with a capping efficiency of 90%. m7GpppAmpG enhances mRNA stability and translation efficiency. m7GpppAmpG is used in mRNA therapeutic research .
CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism .
m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research .
Antiproliferative agent-64 (Compound 76) is an inhibitor for eukaryotic translation initiation factor 4E(eIF4E), that block the secondary structure of mRNA, thereby inhibiting protein translation. Antiproliferative agent-64 inhibits the 5' untranslated region (5'UTR) of c-Myc (c-myc 5'UTR) with an EC50 of 1.2 nM, inhibits 5'UTR encoding tubulin (tub 5'UTR) with an EC50 of 40 nM. Antiproliferative agent-64 inhibits the proliferation of MDA-MB-231 with an EC50 of 7 nM .
(-)-CMLD010509 ((-)-SDS-1-021) is an isomer of CMLD010509 (SDS-1-021) (HY-119271). CMLD010509 (SDS-1-021) is a highly specific inhibitor of the oncogenic translation program supporting multiple myeloma (MM)-including key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. CMLD010509 (SDS-1-021) shows an IC50 below 10 nM for most MM cell lines and induces apoptosis. CMLD010509 (SDS-1-021) is a potent and selective translation inhibitor through an eIF4E phosphorylation-independent mechanism .
PROTAC MNK1 degrader-1 is a selective MNK1PROTAC degrader with a DC50 of 11.92 nM, and a Dmax > 96% in MV4-11 cells. PROTAC MNK1 degrader-1 significantly reduces p-eIF4E (IC50: 22.07 nM), induces apoptosis, and arrests the cell cycle at the G1 phase. PROTAC MNK1 degrader-1 has potent antitumor activity. PROTAC MNK1 degrader-1 has robust antileukemic efficacy in MV4-11 xenograft mice model with acceptable drug safety . Pink: MNK1 ligand (HY-176429); Blue: CRBN ligase ligand (HY-A0003); Black: linker (HY-Y1139); CRBN + linker: HY-176430
m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research .
IF4E protein plays multiple roles in cells, regulating processes such as protein synthesis, mRNA export, RNA processing and splicing. As part of the eIF4F protein complex, IF4E recognizes the mRNA cap and promotes ribosome binding. It is also involved in translation repression and regulation of mRNA stability. In P bodies, IF4E is involved in storing translationally inactive mRNA. In addition, IF4E also plays a role in spermatogenesis, neurogenesis, and mRNA nuclear-cytoplasmic transport. The ability of IF4E to participate in mRNA export relies on binding to the m7G cap and the EIF4E-sensitive element (4ESE). LRPPRC promotes the formation of EIF4E-dependent mRNA export complexes. The action of IF4E changes the composition of nuclear pores and promotes the nuclear export of specific mRNAs. EIF4E Protein, Human is the recombinant human-derived EIF4E protein, expressed by E. coli , with tag free.
EIF4EBP2 is a translation initiation repressor protein that plays a critical regulatory role in synaptic plasticity, learning, and memory. In the hypophosphorylated state, EIF4EBP2 competes with EIF4G1/EIF4G3, forms a complex with EIF4E, and inhibits translation. EIF4EBP2 Protein, Human (His) is the recombinant human-derived EIF4EBP2 protein, expressed by E. coli , with N-6*His labeled tag.
rHuEukaryotic translation initiation factor 4e-binding protein 1/eIF4eBP1, His; Eukaryotic Translation Initiation Factor 4e-Binding Protein 1; 4e-BP1; eIF4e-Binding Protein 1; Phosphorylated Heat- and Acid-Stable Protein Regulated by Insulin 1; PHAS-I; eIF4eBP1
EIF4EBP1 is a translation initiation repressor protein that complexly regulates EIF4E activity. In the hypophosphorylated state, EIF4EBP1 competes with EIF4G1/EIF4G3 to inhibit translation by binding to EIF4E. EIF4EBP1 Protein, Human (His) is the recombinant human-derived EIF4EBP1 protein, expressed by E. coli , with N-6*His labeled tag.
eIF4E Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to eIF4E. It can be used for WB,IHC-P,ICC,FC assays with tag free, in the background of Human, Mouse.
Phospho-eIF4E (Ser209) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to Phospho-eIF4E (Ser209). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.
eIF4eBP1; Eukaryotic translation initiation factor 4e-binding protein 1; 4e-BP1; eIF4e-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat, Hamster
4E BP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to 4E BP1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.
eIF4eBP1; Eukaryotic translation initiation factor 4e-binding protein 1; 4e-BP1; eIF4e-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, IP
Human, Mouse, Rat
Phospho-4E BP1 (Thr46) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 13 kDa, targeting to Phospho-4E BP1 (Thr46). It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.
eIF4E Antibody (YA4825) is a mouse-derived and non-conjugated monoclonal antibody, targeting to eIF4E. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human.
eIF4E Antibody (YA5867) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to eIF4E. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
4e BP3; 4e-BP3; 4eBP3; eIF4e binding protein 3; Eukaryotic initiation factor 4e binding protein 3; Eukaryotic translation initiation factor 4e binding protein 3; OTTHUMP00000159879.
WB
Transfected
EIF4EBP3 Antibody (YA5315) is a mouse-derived and non-conjugated monoclonal antibody, targeting to EIF4EBP3. It can be applicated for WB assays for exogenous protein in transfected cells.
4e-BP2; 4eBP2; 4eBP2_HUMAN; eIF4e binding protein 2; eIF4e-binding protein 2; eIF4ebp2; Eukaryotic translation initiation factor 4e binding protein 1; Eukaryotic translation initiation factor 4e-binding protein 2; PHASII; phosphorylated, heat and acid stable regulated by insulin protein II.
WB
Transfected
4E-BP2 Antibody (YA5314) is a mouse-derived and non-conjugated monoclonal antibody, targeting to 4E-BP2. It can be applicated for WB assays for exogenous protein in transfected cells.
eIF4eBP1; Eukaryotic translation initiation factor 4e-binding protein 1; 4e-BP1; eIF4e-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
4E-BP1 Antibody (YA6024) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 4E-BP1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
eIF4eBP1; Eukaryotic translation initiation factor 4e-binding protein 1; 4e-BP1; eIF4e-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I
WB, ICC/IF, IP, ELISA
Human, Mouse, Rat
Phospho-4E-BP1(Thr37/46) Antibody (YA5780) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to phosphorylated 4E-BP1 (Thr37/46). It can be applicated for WB, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research .
Eif4e Mouse Pre-designed siRNA Set A contains three designed siRNAs for Eif4e gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
EIF4E Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Eif4e Rat Pre-designed siRNA Set A contains three designed siRNAs for Eif4e gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
EIF4E2 Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
EIF4E3 Human Pre-designed siRNA Set A contains three designed siRNAs for EIF4E3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
m7GpppAmpG (m7G(5')ppp(5')(2'OMeA)pG) is a trinucleotide 5′ end cap analog. m7GpppAmpG binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG caps RNA with a capping efficiency of 90%. m7GpppAmpG enhances mRNA stability and translation efficiency. m7GpppAmpG is used in mRNA therapeutic research .
Inquiry Online
Your information is safe with us. * Required Fields.
